Tight Blood Pressure Control in Diabetes: Evidence-Based Review of Treatment Targets in Patients with Diabetes

Blood pressure (BP) targets in diabetic patients stills represent the object of a major debate, fueled by the recent publication of post hoc observational analyses of the INVEST and the ONTARGET trials, suggesting an increased risk of cardiovascular events with tighter control, the J-curve effect, a...

Full description

Saved in:
Bibliographic Details
Published in:Current cardiology reports 2012-02, Vol.14 (1), p.89-96
Main Authors: Reboldi, Gianpaolo, Gentile, Giorgio, Manfreda, Valeria Maria, Angeli, Fabio, Verdecchia, Paolo
Format: Article
Language:English
Subjects:
Antihypertensive Agents - therapeutic use
Blood Pressure - drug effects
Blood Pressure Determination
Cardiology
Diabetes and Cardiovascular Disease (ND Wong
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - drug therapy
Diabetes Mellitus, Type 2 - epidemiology
Diabetic Angiopathies - drug therapy
Diabetic Angiopathies - epidemiology
Diabetic Angiopathies - prevention & control
Evidence-Based Medicine
Female
Humans
Hypertension - drug therapy
Hypertension - epidemiology
Hypertension - etiology
Male
Medicine
Medicine & Public Health
Meta-Analysis as Topic
Myocardial Infarction - drug therapy
Myocardial Infarction - epidemiology
Myocardial Infarction - prevention & control
Randomized Controlled Trials as Topic
Section Editor
Stroke - drug therapy
Stroke - epidemiology
Stroke - prevention & control
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Blood pressure (BP) targets in diabetic patients stills represent the object of a major debate, fueled by the recent publication of post hoc observational analyses of the INVEST and the ONTARGET trials, suggesting an increased risk of cardiovascular events with tighter control, the J-curve effect, and by the results of the ACCORD trial, showing no improvements in the composite primary outcome of nonfatal myocardial infarction, stroke, or cardiovascular death in the intensive BP-lowering arm (
ISSN:1523-3782
1534-3170
DOI:10.1007/s11886-011-0236-8